Oseltamivir drug‐disease modelling in infants with influenza virus infection
Kun Wang, David W Kimberlin, Richard J Whitley, Edward P Acosta, For the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group · 2026
Read Oseltamivir drug‐disease modelling in infants with influenza virus infection by Kun Wang, David W Kimberlin, Richard J Whitley, Edward P Acosta, For the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13519775.txt.
Description
Kun Wang and colleagues modeled how the flu drug oseltamivir should be dosed in infants under two years old. Published in 2026, the study reused drug-level and virus data from an earlier trial run by a national allergy and infectious diseases study group. A population drug model was joined to a viral dynamics model, then run across many doses to find exposures giving 95 percent of maximum viral suppression.
The analysis used hundreds of blood samples from 78 infants, with a median age of eight months, plus virus measures from 62 babies over twelve days. Modeled target exposures were set for both total drug exposure and trough concentration. The authors argue that such modeling can stand in where direct dose-response data are missing, including for preventive once-daily dosing, which fell short for infants already carrying virus. Readers get a dosing compass for a group rarely studied directly.
Catalog record
| CREATOR | Kun Wang, David W Kimberlin, Richard J Whitley, Edward P Acosta, For the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |